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Abstract Latrunculol A is a recently discovered 6,7dihydroxy analog of the potent actin inhibitor latrunculin
A. Latrunculol A has exhibited greater cytotoxicity than
latrunculin A against both murine and human colon tumor
cell lines in vitro. Currently, there are no reports regarding
the bioavailability of latrunculol A in vivo. This study was
undertaken as a prelude to pharmacokinetic assessments
and it is the first work where bioavailability of latrunculol
A was studied. In the present work, a simple plasma preparation and a rapid HPLC method have been developed.
Mouse plasma containing latrunculol A was first treated by
acetonitrile and then centrifuged at 14,000 rpm at 4 °C for
25 min. The supernatant was injected in an HPLC system
comprising a Waters Symmetry NH2 column, a mobile phase
of acetonitrile/water (95/5, v/v), a flow rate of 1.0 mL/min, at
220 nm. The method was validated by parameters including
a good linear correlation, a limit of quantification of 9 ng/mL,
and a good precision with a coefficient variation of 1.65, 1.86,
and 1.26% for 20, 400, and 800 ng/mL, respectively. With this
simple method, excellent separation and sensitivity of
latrunculol A are achieved, thus allowing a rapid analysis of
the plasma samples for absorption, distribution, and metabolism studies.
Keywords Latrunculins . Latrunculol A .
Anti-actin activity . HPLC analysis . Bioavailability
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The latrunculin class of bioactive small molecules continues to command attention as their chemical structures and
biological properties have been explored for nearly three
decades [1]. The octaketide macrolide, latrunculin A [1],
represents one lead member of this class, and a relatively
small assemblage of marine sponges and nudibranchs
constitute the exclusive source of such compounds in nature
[2]. The sustained interest in this class is primarily due to the
pronounced anti-actin activity of the latrunculins [3–5]. In
spite of reports that latrunculin analogs possess in vitro antitumor activity [2, 6–9], there continues to be reduced interest
in developing such compounds as therapeutic leads for solid
tumors [2]. As an important counterpoint, a study exists
showing a positive in vivo therapeutic efficacy for latrunculin A at a dose of 0.3 mg/kg using a sc-implanted A549 lung
tumor xenograft mouse model which yielded a survival ratio
of 146% for (number of survivors in treated group)/(number
of survivors in control group) although the survivors were
not completely tumor-free [10]. As another encouraging
observation, latrunculin A also shares a similar carbon
skeleton with the recently approved anticancer agent
Ixempra™ (ixabepilone) [11], a semi-synthetic analog of
the natural product epitholone B [12] (Fig. 1).
The preceding analysis and the rich representation of
analogs of latrunculin A in our repository prompted this
study to further assess the latrunculin pharmachophore as
an anticancer therapeutics lead. We recently reported that
latrunculol A exhibited greater in vitro inhibition against
murine (colon 38) and human (HCT-116) colon tumor cell
lines vs. latrunculin A [2]. Since little is known about the
bioavailability of latrunculol A, the fundamental next step
consists of a pharmacokinetic assessment. Described below
is a validated method to determine latrunculol A in mouse
plasma by a simple extraction of plasma samples followed
by an isocratic HPLC analysis with UV detection.
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Fig. 1 Structures of latrunculin
A, ixabepilone, epitholone B,
and latrunculol A

latrunculin A

ixabepilone

Since there are no reports regarding the bioavailability of
latrunculol A, two mice per time point were used to assess
the validity of the method in order to further the preclinical
development of latrunculol A.

Experimental
Instruments A Waters Alliance HPLC system [including a
Waters 2690 Separations Module, a Waters 2996 Photodiode Array Detector, a Waters Symmetry NH2 reversedphase column (3.9×300 mm, 10 μm), and the Waters
Empower software] (Milford, Massachusetts, USA) was
used in this study for the determination of latrunculol A. A
Beckman Coulter Allegra 21R Centrifuge (Fullerton,
California, USA) was used to prepare the plasma and
plasma samples for HPLC injection.
Reagents Latrunculol A (purity 98.97%) was isolated as previously described [2], and all solvents were HPLC-grade and
obtained from Burdick & Jackson (Muskegon, Michigan,
USA).
Preparation of plasma and plasma samples Blood samples
from C57 female mice were collected by cardiac puncture
using a 1-mL syringe (with a 25-gauge needle) coated with
heparin. Once the maximum amount of blood was
collected, it was transferred to a 1.5-mL conical centrifuge
tube and centrifuged at 12,000 rpm (equivalent to
14,160×g) at 4 °C for 10 min. Plasma was then transferred
and stored in a freezer at −20 °C. To prepare individual
spiked standards, plasma was thawed for 30 min, different
concentrations of latrunculol A were added to 200 μL of

epitholone B

latrunculol A

plasma samples and acetonitrile was added to each a total
volume of 1 mL, vortexed for 1 min, and centrifuged at
14,000 rpm (equivalent to 19,280×g) at 4 °C for 25 min.
The supernatant was then used for HPLC analysis. To
prepare plasma samples, 4× (v/v) of acetonitrile was added
to each plasma sample (typically, 800 µL acetonitrile was
added to 200 µL plasma), vortexed for 1 min, and
centrifuged the same way as the spiked plasma standards.
The supernatant was then used for HPLC analysis.
HPLC procedure Latrunculol A in the eluted fraction was
determined using a Waters Symmetry NH2 column (3.9×
300 mm) with a 10-μm particle size and a pre-column of
the same material as the stationary phase. The injection
volume was 20 μL. The temperature of the column oven
was room temperature. The mobile phase was acetonitrile/
water (95/5, v/v). The flow rate was 1 mL/min. The lack of
a maximum absorption in the UV range was overcome by
the successful use of a 220 nm detection wavelength to
analyze murine blood samples spiked with latrunculol A.
The results of the analysis are expressed in nanograms of
latrunculol A per milliliter of plasma.
Calibration curve A stock solution of 1,000 ng/mL was prepared in acetonitrile. The calibration curve was obtained with
pooled mouse plasma spiked with known amounts of the
stock solution. The analyte was extracted according to the

Latrunculol A

Table 1 Concentration of latrunculol A in plasma at 1, 4, and 6 h
(two mice per time point)
2

Conc (ng/mL) from 2
individual mice
Average conc (ng/mL)

1h

4h

6h

451, 431

121, 387

86, 363

441

254

225

4

6

8
Time (Min)

10

12

14

Fig. 2 A typical chromatogram of 20 ng/mL latrunculol A (spiked
plasma) at 220 nm. Acetonitrile/water (95/5, v/v) was used as the
mobile phase and the flow rate was 1 mL/min. The peak at 3.4 min
resulted from plasma (verified by a plasma control)

A rapid method for the detection of latrunculol A in plasma
Table 2 Assay of a latrunculol A sample (300 ng/mL) over a period
of 3 days
Intra-day assay

Animal Care and Use Committee (IACUC) Guidelines for
the care and management of laboratory animals.

Results (ng/mL)

Day 1, morning
Day 1, afternoon
Day 1, night
Avg ± SD
RSD (%)
Avg from Day 1

300.90
301.54
301.19
301.21±0.32
0.11
301.21

Day 2
Day 3
Avg ± SD
RSD (%)

299.83
298.97
300.00±1.13
0.38

protocol described above. The calibration curve was obtained
by plotting the peak area of latrunculol A against its concentration in seven spiked plasma standards (1,000, 800, 400, 200,
100, 20, and 10 ng/mL) and performing a linear regression.
Animal study Latrunculol A was administered i.p. to C57
female mice at 3.1 mg/kg (injection of 0.25 mL of
0.25 mg/mL of latrunculol A in saline, containing 5%
DMSO and 5% cremophor/propylene glycol 60/40, v/v);
the animals were sacrificed at 1, 4, and 6 h after drug
administration. Blood was taken by cardiac puncture and
transferred to a tube containing heparin as anticoagulant.
Plasma was obtained by centrifugation, and the analyte was
extracted using the procedure described above. Animal
treatment was in full accordance with the Institutional
Table 3 Assay results of three
samples with known concentrations (100, 300, and 600 ng/mL)
under various HPLC
conditions
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Results and discussion
The data gathered allows detection of latrunculol A over a
wide range of concentrations. We also observed that it is
stable in plasma for up to 72 h. The method developed here
was validated according to the U.S. Pharmacopeia [13] and
the analytical performance parameters considered were
selectivity (specificity), linearity, accuracy, precision, sensitivity, and ruggedness. To assess the validity of the technique,
C57 female mice (average weight 20 g) were injected i.p. with
latrunculol A (3.1 mg/kg). Blood samples from two mice were
taken by cardiac puncture at 1, 4, and 6 h, processed, and
analyzed as described in the “Experimental” section. The
results shown in Table 1 indicate that a significant amount of
latrunculol A was found in the plasma over the 6-h testing
period.
The key analytical details pertaining to the method
described above require additional comments.
The six parameters used to validate the method are as
follows: (1) Selectivity, latrunculol A was quantified at
220 nm wherein no significant interfering peaks were
observed. A typical chromatogram at this wavelength
shown in Fig. 2 indicated that latrunculol A was well
resolved and free from interference peaks. The use of a
photodiode array detector allowed the confirmation of the
identity of the chromatographic peak not only by its
retention time but also by its spectrum. (2) Linearity,
calibration curves of latrunculol A were prepared to

Change
level

Sample 1

Sample 2

Sample 3

Effect of mobile phase variation on assay
(ng/mL)
Acetonitrile (%)
94
95
96
Avg±SD
RSD (%)

−1
0
+1

99.82
99.72
100.01
99.85±0.15
0.15

300.15
301.94
301.61
301.23±0.95
0.32

600.01
599.47
599.25
599.58±0.39
0.07

Effect of flow rate variation on assay (ng/mL)
Flow rate (mL/min)
0.9
1.0
1.1
Avg±SD
RSD (%)

−0.1
0
+0.1

100.07
99.72
99.67
99.82±0.22
0.22

300.04
301.94
301.52
301.17±1.00
0.33

600.41
599.47
598.00
599.29±1.21
0.20
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determine the linearity of the method over the range of 10–
1,000 ng/mL. Integrated peak areas were plotted against
analyte concentration, and linear regression was performed
by the least-squares method. The calibration curve generated using plasma as matrix showed a square of correlation
coefficient of 0.9992. (3) Accuracy, the accuracy of the
analytical method was determined by application of the
method to analytes of known concentrations. Three spiked
plasma samples (100, 300, and 600 ng/mL) were prepared
and analyzed and the assay results were 99.72, 301.94, and
599.47 ng/mL, indicating a recovery of 99.72%, 100.67%,
and 99.92% for these samples. Therefore, the method is
accurate. (4) Precision, the precision of the analytical
method was determined by analyzing three homogeneous
samples of plasma spiked with three levels of latrunculol A
(20, 400, and 800 ng/mL, respectively) in six replicates.
Peak areas were considered for the determination. The
precision, expressed as the coefficient of variation (CV),
was 1.65%, 1.86%, and 1.26% for each individual sample.
These values were lower than those normally acceptable in
the U.S. Pharmacopeia [13] indicating that the method is
precise. (5) Sensitivity, the limit of detection (LOD) and the
limit of quantification (LOQ) were obtained by first
injecting six replicates of a sample at 5 ng/mL; the standard
deviation (StDev) was multiplied by 3 and by 10 and the
calibration curve was used to obtain the LOD and LOQ,
respectively. At 220 nm, the LOD for latrunculol A was
3 ng/ml and the LOQ was 9 ng/ml. (6) Ruggedness
(robustness), ruggedness was shown by assaying a spiked
plasma sample with known concentration (300 ng/mL) on
three consecutive days employing the corresponding
linearity curve generated on the day the sample was
assayed. As shown in Table 2, intra- and inter-day assay
results of a particular sample are essentially the same,
indicating an acceptable ruggedness of the method for
intra- and inter-day assay studies. In addition, three spiked
samples (100, 300, and 600 ng/mL) were analyzed using
slightly modified mobile phases and different flow rates.
As shown in Table 3, when acetonitrile/water ratio
was changed to 94/6 or 96/4 as compared to the normal
95/5 (v/v) ratio, no significant differences were observed in
the assay results as indicated by the relative standard
deviation (RSD). When the flow rate was reduced/
increased to 0.9/1.1 mL/min as compared to the normal
1 mL/min, the assay results were essentially the same.
These assay results further indicate that the present method
is rugged with respect to minor changes of the mobile
phase or the flow rate.

J. Shaw et al.

In summary, we have shown that each of the six
parameters discussed above provides a good basis for
further bio-evaluation of latrunculin A. The method
described herein is suitable for analyzing plasma samples
of latrunculol A. Compared with conventional methods, our
protocol has the advantage that time-consuming procedures
(such as solid-phase extraction, drying, and reconstitution)
are not necessary. Until now, no data have been published
concerning absorption, bioavailability, and tissue distribution of latrunculol A. We have successfully developed a
simple method to determine latrunculol A in plasma, and
we have also detected for the first time the absorption of
this compound in mouse blood. Further experiments will
now be possible to evaluate and understand the pharmacokinetics and efficacy of latrunculol A in mice.
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